GSK plc Earnings beat, Revenue misses In Q2
Investing.com - GSK plc reported on Wednesday second quarter {{erl-6612||earnings that beat analysts' forecasts and revenue that fell short of expectations. GSK plc announced earnings per...
Neutral
or
GSK plc News & Analysis
-
-
New GSK Q2 Highlights: Shingles Vaccine Back In Demand, Antibiotics Recover, Forecast Boost
GSK Plc's (NYSE: GSK) Q2 turnover reached £6.9 billion, up 19% Y/Y on the actual exchange rate (AER) and 13% on a constant exchange rate (CER) basis. Specialty Medicines turnover was £2.7...
-
GSK lifts full-year forecast, days after consumer health spinoff
(Reuters) – GSK on Wednesday lifted its full-year forecast, boosted by reinvigorated demand for its blockbuster Shingrix vaccine, days after overhauling the business with the spinoff of...
-
This Analyst Says GSK Spin-Off Haleon Offers "Best Of Both Consumer Worlds"
Citi group has initiated coverage on GSK plc's (NYSE: GSK) consumer healthcare spin-off Haleon Plc (NYSE: HLN) with a Buy rating and a price target of 360p. "We see the company as the best...
-
Friday’s Top Analyst Upgrades and Downgrades: Alcoa, Enterprise Products Partners, GSK, Nordstrom, Southwestern Energy, Tesla and More
Friday's top analyst upgrades and downgrades included Alcoa, Blue Apron, Brixmor Property, Enterprise Products Partners, FIGS, GSK, Healthcare Realty Trust, Nordstrom, Range Resources,...
-
What Does the Haleon Spinoff Mean for GSK Shareholders?
British pharmaceuticals giant GlaxoSmithKline (GB:GSK) (GSK) completed the much-anticipated spinoff and subsequent public listing of its consumer health business Haleon on July 18. The...
-
GSK Completes Spin Off Of Its Consumer Healthcare Business
GSK plc (NYSE: GSK) has completed the demerger of the Consumer Healthcare business to form the Haleon Group. Reuters reported that shares in Haleon started trading at 330 pence on Monday...
-
European Stock Futures Higher; ECB Meeting Looms Large
By Peter Nurse Investing.com - European stock markets are expected to open higher Monday, helped by a bounce on Wall Street, but investors will be on edge ahead of a key meeting of the...
-
Factbox-GSK spins off consumer health business worth up to $57 billion
By Natalie Grover (Reuters) – British drugmaker GSK will spin off its consumer health business Haleon worth up to an estimated 48 billion pounds ($57 billion) on Monday in the biggest...
-
After bruising year, GSK approaches consumer split in better health
By Natalie Grover LONDON (Reuters) – Things are looking up for GSK and its chief Emma Walmsley as the British drugs giant prepares to spin off its consumer health business on Monday in...
-
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus GSK Prepares US For Upcoming Flu Season With Over 50M Vaccine Doses GSK plc (NYSE: GSK)...
-
U.K. shares higher at close of trade; Investing.com United Kingdom 100 up 0.13%
Investing.com – U.K. equities were higher at the close on Friday, as gains in the Automobiles & Parts, Industrial Transportation and Construction & Materials sectors propelled shares...
-
GSK’s new vaccine hire looks beyond COVID in quest for next hit: ‘The potential is there to really make a much better flu vaccine’
GSK Plc is planning to launch a COVID shot that comes almost two years after Pfizer Inc. took the world by storm. For Phil Dormitzer, it’s a reminder of why he was hired at the UK drugmaker:...
-
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Europe Backs Novavax's COVID-19 Shot For Adolescents The European Union has recommended...
-
Sanofi, GSK's Covid-19 Variant Shot Effective Against Omicron
The companies reported promising trial results for their Covid-19 vaccine that showed the shot—developed to target the Beta strain of the virus—was particularly effective against the Omicron...
-
Sanofi, GSK say their next-generation COVID-19 booster has 72% efficacy against omicron
Sanofi and GlaxoSmithKline said Friday that their experimental bivalent COVID-19 booster had a 72% efficacy rate against omicron, and they now plan to submit the data to regulators. The...
-
GSK, Novartis pledge funds for diseases that mostly affect the poor
By Natalie Grover and Jennifer Rigby LONDON (Reuters) – GSK and Novartis on Thursday reinforced commitments to address neglected tropical diseases, as world leaders and health experts...
-
Covid-19 Variant Shot From Sanofi, GSK Shows Strong Response to Omicron
Results from two new studies are the latest indication that tweaking vaccines can nudge antibody responses in the direction of new variants, possibly helping to shore up immunity as the...
-
European Stocks Sharply Lower; U.K. GDP Slumps in April
By Peter Nurse Investing.com - European stock markets traded lower Monday, with weak UK growth data raising fears of an economic slowdown in the region just as central banks move to address...
-
European Stocks Lower; Sentiment Hit by ECB Tightening Pledge
By Peter Nurse Investing.com - European stock markets weakened Friday as investors digested the rate hike guidance from the European Central Bank ahead of the release of key U.S. inflation...
-
GSK’s RSV vaccine succeeds in late-stage trial for older adults
LONDON (Reuters) – GSK’s vaccine for respiratory syncytial virus (RSV) was successful in a late-stage trial involving older adults, the company said on Friday.
-
European Stocks Higher; ECB Meeting Looms Large
By Peter Nurse Investing.com - European stock markets traded higher Monday, starting an important week on a positive note as investors look ahead to a European Central Bank meeting as well...
-
GSK’s measles prevention vaccine gets U.S. approval
(Reuters) – British drugmaker GSK said on Monday its vaccine, Priorix, was approved by the U.S. Food and DrugAdministration (FDA) for the prevention of measles, mumps and rubella for...
-
Pfizer Will Exit GSK’s Consumer Health Business Haleon Upon Listing
Pfizer Inc. (NYSE:PFE) revealed its plans to sell its 32% ownership stake in Haleon in a disciplined manner, citing maximization of value for Pfizer shareholders as the reason. Haleon is due...
-
Pfizer Changes Its Mind, Will Sell Down Stake in GSK's Haleon Unit
By Geoffrey Smith Investing.com -- Pfizer (NYSE:PFE) will sell down its stake in Haleon, the consumer healthcare unit of GSK (LON:GSK), after its listing in London planned for later...
-
Pfizer to exit GSK’s consumer health arm after spin-off
LONDON (Reuters) – Pfizer plans to exit its 32% stake in Haleon, its consumer health joint venture with GSK, after the business is spun off as an independent company in July, GSK said on...
-
Unilever Surges After Appointing Activist Nelson Peltz to its Board
By Geoffrey Smith Investing.com -- Unilever (AS:ULVR) stock rose 7.48% at the open on Tuesday after the consumer giant said it had appointed US-based activist investor Nelson Peltz as a...
-
GlaxoSmithKline Earnings, Revenue beat In Q1
Investing.com - GlaxoSmithKline (LON:GSK) reported on Wednesday first quarter {{erl-6612||earnings that beat analysts' forecasts and revenue that topped expectations. GlaxoSmithKline...
-
GlaxoSmithKline ADR Earnings, Revenue beat In Q1
Investing.com - GlaxoSmithKline (LON:GSK) ADR reported first quarter {{erl-22459||earnings that beat analysts' expectations on Wednesday and revenue that topped forecasts. The firm...
-
GSK Agrees on $1.9bn Deal to Acquire Sierra Oncology
By Sam Boughedda Investing.com -- GlaxoSmithKline (LON:GSK) PLC ADR (NYSE:GSK) announced Wednesday that it has entered into an agreement to acquire Sierra Oncology Inc (NASDAQ:SRRA), a...
-
U.K. shares higher at close of trade; Investing.com United Kingdom 100 up 1.09%
Investing.com – U.K. equities were higher at the close on Wednesday, as gains in the Automobiles & Parts, Industrial Transportation and Travel & Leisure sectors propelled shares higher. At...
-
GlaxoSmithKline Earnings, Revenue beat In Q4
Investing.com - GlaxoSmithKline (LON:GSK) reported on Wednesday fourth quarter {{erl-6612||earnings that beat analysts' forecasts and revenue that topped expectations. GlaxoSmithKline...
-
European Stocks Firm; GSK Gains on Covid-Related Sales
By Peter Nurse Investing.com -- European stock markets traded higher Wednesday on a busy day for corporate earnings, but investors are still keeping a wary eye on the tense situation in...
-
Asian Stocks Down, Bets on Fed Interest Rate Hikes Continue Upward Trend
By Gina Lee Investing.com – Asia Pacific stocks were mostly down on Monday morning, while U.S. futures were down, as bets that the U.S. Federal Reserve will hike interest rates also weighed...
-
The Week Ahead
US jobsIn the week ending Jan 22, the advance figure for seasonally adjusted initial claims was 260 000, a decrease of 30 000 from the previous week's revised level. The previous week's...
-
U.K. shares lower at close of trade; Investing.com United Kingdom 100 down 1.23%
Investing.com – U.K. equities were lower at the close on Friday, as losses in the Travel & Leisure, Automobiles & Parts and Mining sectors propelled shares lower. At the close in London,...
-
U.K. shares lower at close of trade; Investing.com United Kingdom 100 down 0.42%
Investing.com – U.K. equities were lower at the close on Thursday, as losses in the Mining, Pharmaceuticals & Biotech and Fixed Line Telecommunications sectors propelled shares lower. At...
-
U.K. shares lower at close of trade; Investing.com United Kingdom 100 down 0.04%
Investing.com – U.K. equities were lower at the close on Thursday, as losses in the Oil & Gas Producers, Automobiles & Parts and Mobile Telecommunications sectors propelled shares lower. At...
-
GlaxoSmithKline Earnings, Revenue beat In Q3
Investing.com - GlaxoSmithKline (LON:GSK) reported on Wednesday third quarter {{erl-6612||earnings that beat analysts' forecasts and revenue that topped expectations. GlaxoSmithKline...
-
GSK Gains on Report of Aggressive Private Equity Valuation for Consumer Unit
By Dhirendra Tripathi Investing.com – GlaxoSmithKline (LON:GSK) ADRs (NYSE:GSK) traded 2.5% higher in Tuesday’s premarket after a newswire report suggesting the spin off of its...
-
GlaxoSmithKline Earnings, Revenue beat In Q2
Investing.com - GlaxoSmithKline (LON:GSK) reported on Wednesday second quarter {{erl-6612||earnings that beat analysts' forecasts and revenue that topped expectations. GlaxoSmithKline...
-
GlaxoSmithKline Earnings beat, Revenue misses In Q1
Investing.com - GlaxoSmithKline (LON:GSK) reported on Wednesday first quarter {{erl-6612||earnings that beat analysts' forecasts and revenue that fell short of...
-
GLOBAL MARKETS-Just don't mention the 'T' word
* Equities lack trend as earnings roll in, bond yields creep up* Fed expected to stay course but outlook is improving* Copper comes off decade high* Apple (NASDAQ:AAPL), Facebook...
-
UPDATE 1-UK Stocks-Factors to watch on April 16
(Updates futures, adds news items)April 16 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Friday, with futures FFIc1 up 0.2% ahead of market open.* OCADO: Ocado OCDO.L...
-
UK Stocks-Factors to watch on April 16
April 16 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening steady on Friday, with futures FFIc1 marginally down 0.01%.* GLOBALWORTH: A top executive at German real estate company...
-
U.K. shares higher at close of trade; Investing.com United Kingdom 100 up 0.76%
Investing.com – U.K. equities were higher at the close on Thursday, as gains in the Pharmaceuticals & Biotech, Mining and General Industrial sectors propelled shares higher. At the close in...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
